MEPRON
LOE ApproachingNDAORALTABLETPriority Review
Approved
Nov 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
MEPRON by GSK is [see microbiology ()] . Approved for pneumocystis jirovecii pneumonia (pcp) in adults, adolescents (aged 13 years, older). First approved in 1992.
Drug data last refreshed 6d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MEPRON is an oral tablet containing atovaquone, a small-molecule antiprotozoal agent indicated for treatment of Pneumocystis jirovecii pneumonia (PCP) in adults and adolescents aged 13 years and older. The drug works by disrupting the electron transport chain in the mitochondria of susceptible organisms. It represents a non-first-line alternative for PCP prophylaxis and treatment in immunocompromised patients.
$0.322MPart D
LOE ApproachingDeclining
Mature product with minimal claims volume and approaching loss of exclusivity signals a consolidating team focused on retention rather than growth initiatives.
Mechanism of Action
[see Microbiology ()] .
Worked on MEPRON at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.